KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Common Equity (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Common Equity for 7 consecutive years, with $616.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 14.96% to $616.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $616.3 million through Dec 2025, down 14.96% year-over-year, with the annual reading at $616.3 million for FY2025, 14.96% down from the prior year.
  • Common Equity hit $616.3 million in Q4 2025 for GoodRx Holdings, up from $600.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $895.4 million in Q2 2023 to a low of $600.7 million in Q3 2025.
  • Historically, Common Equity has averaged $753.1 million across 5 years, with a median of $774.2 million in 2022.
  • Biggest five-year swings in Common Equity: soared 180.29% in 2021 and later dropped 25.24% in 2024.
  • Year by year, Common Equity stood at $831.7 million in 2021, then dropped by 2.03% to $814.8 million in 2022, then decreased by 6.49% to $762.0 million in 2023, then dropped by 4.9% to $724.7 million in 2024, then fell by 14.96% to $616.3 million in 2025.
  • Business Quant data shows Common Equity for GDRX at $616.3 million in Q4 2025, $600.7 million in Q3 2025, and $643.0 million in Q2 2025.